Chapter 1.    SLEEP DISORDER TREATMENT DRUGS MARKET – Scope & Methodology

1.1. Market Segmentation

1.2. Assumptions

1.3. Research Methodology

1.4. Primary Sources

1.5. Secondary Sources

Chapter 2.    SLEEP DISORDER TREATMENT DRUGS MARKET – Executive Summary

2.1. Market Size & Forecast – (2023 – 2030) ($M/$Bn)

2.2. Key Trends & Insights

2.3. COVID-19 Impact Analysis

 2.3.1. Impact during 2023 - 2030

  2.3.2. Impact on Supply – Demand

Chapter 3.    SLEEP DISORDER TREATMENT DRUGS MARKET – Competition Scenario

3.1. Market Share Analysis

3.2. Product Benchmarking

3.3. Competitive Strategy & Development Scenario

3.4. Competitive Pricing Analysis

3.5. Supplier - Distributor Analysis

Chapter 4.   SLEEP DISORDER TREATMENT DRUGS MARKET - Entry Scenario

4.1. Case Studies – Start-up/Thriving Companies

4.2. Regulatorycenario - By Region

4.3 Customer Analysis

4.4. Porter's Five Force Model

       4.4.1. Bargaining Power of Suppliers

       4.4.2. Bargaining Powers of Customers

       4.4.3. Threat of New Entrants

       4.4.4. Rivalry among Existing Players

       4.4.5. Threat of Substitutes

Chapter 5.    SLEEP DISORDER TREATMENT DRUGS MARKET  - Landscape

5.1. Value Chain Analysis – Key Stakeholders Impact Analysis

5.2. Market Drivers

5.3. Market Restraints/Challenges

5.4. Market Opportunities

Chapter 6. SLEEP DISORDER TREATMENT DRUGS MARKET – By Disorder Type

6.1. Sleep apnea

6.2. Obstructive sleep apnea

6.3. Central sleep apnea

6.4. Complex sleep apnea

6.5. Insomnia

6.6. Restless legs syndrome (RLS)

6.7. Narcolepsy

6.8. Others

Chapter 7. SLEEP DISORDER TREATMENT DRUGS MARKET – By Product

7.1. Diagnostics

7.2. Actigraphy systems

7.3. Polysomnography (PSG) device

7.4. Respiratory polygraph

7.5. Sleep screening devices

7.6. Home sleep tests

7.7. Others

7.8. Therapeutics

7.9. Cognitive behavioral therapy

7.10. Therapeutic devices

7.11. Airway clearance system

7.12. Adaptive servo-ventilation (ASV)

7.13. Positive airway pressure (PAP) devices

7.14. Oral appliances

7.15. Oxygen devices

7.16. Others

7.17. Medication therapy

7.18. Benzodiazepines

7.19. Dual orexin receptor antagonists

7.20. Melatonin receptor agonists

7.21. Antidepressants

7.22. Others

Chapter 8.   SLEEP DISORDER TREATMENT DRUGS MARKET – By Region

8.1. North America

8.2. Europe

8.3. Asia-P2acific

8.4. Latin America

8.5. The Middle East

8.6. Africa

Chapter 9.    SLEEP DISORDER TREATMENT DRUGS MARKET – By Companies

9.1. Companies 1

9.2. Companies 2

9.3. Companies 3 

9.4. Companies 4

9.5. Companies 5

9.6. Companies 6

9.7. Companies 7

9.8. Companies 8

9.9. Companies 9

9.10. Companies 10